Neorich Biopharma Tech Co., Limited
OOTC:PHBID0.45
USD
+0.00
(+0.87%)
ISIN
US71716C2089
CUSIP
71716C208
Return %
Stock
S&P 500
1Y
-77.50
14.20
3Y
-71.87
81.12
5Y
-99.02
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Quarterly Revenue
USD
•
in mil. unless spec.Quarterly Earnings Per Share
USD
•
in mil. unless spec.Quarterly Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Dianming Ren
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- New York United States
- Similar Companies
- Business
- Neorich Biopharma Tech Co., Limited is a biotechnology and life sciences company engaged in the research, development, manufacturing, and commercial distribution of biopharmaceuticals, botanical medicines, and natural health formulations. The company operates across multiple life sciences segments, offering a diverse portfolio of products and technical solutions that includes botanical pharmaceuticals, active pharmaceutical ingredients (APIs), and standardized herbal extracts; nutritional supplements, dietary wellness products, and functional healthcare formulations targeting metabolic health and immune support; proprietary biotherapeutic candidate compounds; and specialized contract research, laboratory analytical testing, regulatory compliance validation, and biotechnical consulting services for life sciences enterprises. Neorich Biopharma Tech Co., Limited serves pharmaceutical manufacturers, healthcare institutions, commercial distributors, and consumer wellness markets across the Asia-Pacific region and North America. Founded in 2004 and headquartered in Hong Kong, the company maintains operational and corporate affiliations in Greater China and the United States. In recent developments, the company completed a major corporate reorganization and corporate rebranding to Neorich Biopharma Tech Co., Limited, reflecting a strategic shift toward advanced biopharmaceutical innovation and cross-border commercialization of botanical therapeutics. As part of this corporate restructuring, the company initiated a capital reclassification with its common stock trading under the interim OTC symbol PHBID, while simultaneously entering strategic research collaborations and distribution partnerships with regional life sciences institutes and healthcare distributors to accelerate the market rollout of its proprietary natural health and biopharmaceutical product lines.